Grand generalisations do not necessarily flow from Daiichi Sankyo's acquisition of India’s largest pharmaceutical firm, Ranbaxy. As pointed out by our trusted source – a former CEO of Ranbaxy – this deal had many company-specific causes. Yet it highlights an intensifying ferment in India's pharmaceutical sector as a combination of global and domestic factors focuses attention on generics.
As the imminent wave of patent expiries pushes Big Pharma towards generics, two types of Indian...
Sorry, you do not have access to this page because you are not logged in.
If you are not a subscriber or a trialist and you want to discuss how to access our work please:
Trusted Sources helps clients identify investment opportunities in emerging markets, exploit them with greater confidence and stay alert to associated risks.
Learn more about our approach, our team and our research, as well as our media appearances.
